Published in

Wiley, Cochrane Library, 3(2017), 2016

DOI: 10.1002/14651858.cd009753.pub2

Protocols

DOI: 10.1002/14651858.cd009753

Links

Tools

Export citation

Search in Google Scholar

Fibrates for primary prevention of cardiovascular disease events

Journal article published in 2012 by Tobias Jakob, Stefan Schandelmaier, Alain J. Nordmann, Ignacio Ferreira-González, Benjamin Kasenda, Ramon Saccilotto, Dirk Bassler, Neera Bhatnagar, Matthias Briel ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the clinical benefit and harm of fibrates versus placebo or usual care or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone for the primary prevention of CVD events and mortality.